The 41st OLF (Osaka Liver Forum) Research and Presentation Meeting was held on Friday, May 15, 2026, at RIHGA Royal Hotel Osaka West Wing, 2nd floor "Sanraku no Ma". The event was attended by many doctors and was a great success, with lively discussions and exchanges of opinions on liver disease treatment and research.
A wide variety of topics were presented in this program, including immunotherapy for unresectable hepatocellular carcinoma, the relationship between MASLD and sleep apnea syndrome (OSA), retention rate in alcoholic cirrhosis, prediction of treatment efficacy of combined immunotherapy for liver cancer, and search for new biomarkers in chronic hepatitis B. Both the young researchers' and general sessions were very active, and the discussions were very meaningful for the development of daily practice and future research.
We would like to express our sincere appreciation to all the speakers and participants, as well as to all those who worked so hard to make this event possible.
OLF (Osaka Liver Forum) will continue to provide a forum for academic exchange that contributes to the development of medical treatment and research in the field of liver disease.
Program
- Young SessionsChairperson: Dr. Ayako Kambe, Suita Municipal Hospital
Kansai Rosai Hospital Dr. Tsuyoyuki Iwamoto
- Subject IInitial experience with nivolumab plus ipilimumab for unresectable hepatocellular carcinoma at our hospital."
Osaka Medical Center Dr. Kazuhide Fujihira
- Title IISilent-OSA in patients with MASLD."
Dr. Yu Tsumuro, Kaizuka Municipal Hospital
- General Session
- Subject IIIChairperson: Dr. Seiichi Tawara, Osaka Acute & Comprehensive Medical Center
"A Study of the Rate of Continuity of Care and Factors Contributing to It in Alcoholic Liver Cirrhosis."
Kansai Rosai Hospital Dr. Yuna Ohira
- Title IVChairperson: Dr. Satoshi Tanaka, Osaka Medical Center
Immunokinetics and Therapeutic Effectiveness of Combined Immunotherapy for Liver Cancer in the OLF Multicenter Cohort."
Dr. Kei Nishio, JCHO Osaka Hospital
- Title VChairperson: Dr. Kengo Matsumoto, Toyonaka Municipal Hospital
A New Mechanism of Immunotherapy Resistance in Hepatocellular Carcinoma: Is the NRF2-COX2 Pathway a Predictive Marker of Therapeutic Response?
Osaka International Cancer Center Dr. Shuhei Yamamoto
- Title VIChairperson: Dr. Kazuho Imanaka, Itami Municipal Hospital
Clinical Implementation of Sleep Apnea Pickup in MASLD Practice."
Dr. Shigenobu Kakita, Kaizuka Municipal Hospital
- Title VIIChairperson: Dr. Ei Ishida, Ikeda Municipal Hospital
"Involvement of low HBs antigen and monocyte-derived IL-1β in chronic hepatitis B and its potential as a predictive marker."
Dr. Satoshi Shino, Osaka University Graduate School of Medicine
For more information on the day's meeting, please see the Instagram post below.
